B38-CAP is an ACE2-like enzyme derived from bacteria. Unlike the human ACE2 enzyme, the SARS-CoV-2 virus does not bind to B38-CAP.
B38-CAP participates in ACE2-like catalytic activity, e.g. converting Ang II to Ang (1-7). This ACE2-like activity is capable of suppressing hypertension and cardiac dysfunction.
B38-CAP is being studied as a possible treatment for COVID-19.
See also
- List of COVID-19 ARB trials - page collecting information on trials of renin-angiotensin system related drugs for COVID-19.
